FOXO4-DRI

Overview

FOXO4-DRI is a synthetic D-retro-inverso peptide engineered to mimic a region of the FOXO4 transcription factor and competitively block the FOXO4-p53 interaction. The D-retro-inverso architecture (D-amino acids in reverse sequence) confers protease resistance while preserving the relevant binding surface.

Research Background

FOXO4-DRI emerged from work by Peter de Keizer and colleagues identifying the FOXO4-p53 axis as a key regulator of senescent cell viability. It has been investigated in research on cellular senescence, vascular aging, fibrosis, age-related testosterone biology, and senolytic pharmacology.

Storage & Handling

Store lyophilized peptide at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within recommended timeframes. Handle under sterile laboratory conditions and avoid repeated freeze-thaw cycles.

Disclaimer:
This product is for laboratory research use only. It is not intended for human or animal consumption or for use in any diagnostic, therapeutic, or clinical applications.

FOXO4-DRI competes with endogenous FOXO4 for binding to p53, specifically the p53 transactivation domain. By preventing FOXO4 from sequestering activated p53 in the nucleus of senescent cells, the peptide enables p53 nuclear export to mitochondria, triggering BAX/Caspase-3-mediated apoptosis selectively in senescent cells while sparing non-senescent cells.

FOXO4-DRI is studied in research on cellular senescence, senolytic pharmacology, vascular aging, fibrotic disease models, and reproductive aging. It is a reference compound in senolytic peptide research.